Pfizer

This early-stage study aims to test the safety and side effects of a new vaccine designed to protect against E. coli bacteria. The trial will enroll 310 healthy adults aged 18-64 who will receive injections and be monitored for reactions. Researchers will track common vaccine sid…

This study is testing new mRNA-based flu vaccines to see how safe they are and how well they trigger the body's immune response against influenza. It involves 770 healthy adults who will receive one shot of either an experimental mRNA vaccine or an approved flu vaccine for compar…

This study is checking if giving the RSV vaccine during multiple pregnancies is safe for both mothers and babies. It involves 550 pregnant women who previously received the RSV vaccine, with some getting another dose and others getting a placebo. Researchers will monitor mothers …

This study is testing a new vaccine, called VLA15, designed to prevent Lyme disease. It will enroll 200 healthy adults aged 18-44 to see how safe the vaccine is and how well it triggers an immune response when given on different schedules. Participants will receive four vaccine s…

This large study is testing whether a new vaccine can prevent C. difficile infections, a serious cause of diarrhea, in adults aged 65 and older. About 32,000 participants will receive either the real vaccine or a placebo (saltwater) shot and be followed for up to 3.5 years. The m…

This study aims to measure how well Pfizer's 20-strain pneumonia vaccine protects adults 65 and older from severe, lung infection confirmed by chest imaging. It will enroll 12,500 participants who are hospitalized with suspected pneumonia. Researchers will compare infection rates…

This large study is testing whether a new vaccine given to healthy pregnant women can safely protect their newborns from Group B Strep (GBS), a serious bacterial infection. About 6,000 participants will receive either the vaccine or a placebo (saltwater) shot during pregnancy. Re…

This large Phase 3 study aims to see if a new drug called PF-08634404, when given with chemotherapy, works better and is as safe as the current standard treatment (pembrolizumab with chemotherapy) for adults with advanced non-small cell lung cancer that has spread. About 1,410 pa…

This study is testing whether people with severe hemophilia A can safely switch from their current preventive medication (emicizumab) to a new one (marstacimab). Researchers want to see how the body handles the new drug and check for side effects. The study involves about 15 part…

This study is testing whether a new medicine called PF-07275315 can help people with moderate-to-severe COPD breathe better and have fewer serious flare-ups. About 1,156 adults with COPD who have had at least two recent flare-ups will receive either the actual medicine or placebo…

This study is monitoring potential eye side effects in cervical cancer patients receiving TIVDAK treatment. The drug is already approved for recurrent or metastatic cervical cancer, but researchers want to better understand how it affects patients' eyes. Participants will receive…

This study is testing a new drug, PF-07248144, to see if it is safe and can help control advanced cancers that have spread. It will be given to about 320 people with advanced breast, prostate, or lung cancer, both by itself and combined with other cancer drugs. The main goals are…

This study is testing if a medication called rimegepant can prevent migraine headaches that occur around a woman's menstrual period. About 723 women aged 18 to 45 who regularly get menstrual migraines will take either the study drug or a placebo (inactive pill) for a few days eac…

This study is testing whether a new oral medication called ibuzatrelvir, given alone or with the existing IV drug remdesivir, works better than remdesivir alone to treat COVID-19 in adults with severely weakened immune systems. The trial will enroll 300 participants who have rece…

This study is for adults with advanced non-small cell lung cancer that has spread and has stopped responding to standard treatments. The goal is to see if a new drug, PF-08046054, works better and is safer than the current standard chemotherapy, docetaxel. About 680 participants …

This study is testing whether adding a new drug called Sigvotatug Vedotin to an existing immunotherapy (pembrolizumab) works better than the immunotherapy alone for advanced non-small cell lung cancer. It will involve about 714 adults whose cancer has high levels of a specific pr…

This study is testing whether a new drug called PF-08634404 works better when combined with standard chemotherapy for extensive-stage small cell lung cancer, a fast-spreading type of lung cancer. Researchers will enroll 550 adults who haven't received prior chemotherapy for this …

This study is testing an oral medication called ritlecitinib to see if it can safely reduce itchy hives and swelling in adults with chronic spontaneous urticaria (CSU) that isn't controlled by standard allergy medicines. About 200 participants will be randomly assigned to take ei…

This study aims to see how safe and effective the daily pill abrocitinib is for treating moderate-to-severe eczema in real-world medical practice. It will follow about 180 adults with this chronic skin condition for two years while they take the medication. The goal is to underst…

This study is testing whether adding a new drug called mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with metastatic prostate cancer that still responds to hormone therapy. The goal is to see if the combination can delay cancer …

This study aims to see how well the approved drug ritlecitinib works for people with severe alopecia areata (an autoimmune hair loss condition) in real-world clinic settings, not just in controlled trials. It will follow 850 patients aged 12 and older who are already prescribed t…

This study is monitoring the safety and effectiveness of Litfulo capsules in real-world patients with severe alopecia areata (patchy hair loss). It will follow 3,000 patients in Korea for up to 48 weeks to track any side effects and measure how much hair regrows. The goal is to u…

This study is testing whether adding a new drug called elranatamab to two existing medications works better than the current standard treatment for newly diagnosed multiple myeloma. The trial involves 1,116 adults with this blood cancer who cannot receive or are delaying a stem c…

This study monitors the safety and effectiveness of Xeljanz in children with juvenile arthritis during routine medical care in Korea. It follows 10 patients aged 2-18 who are already prescribed Xeljanz for up to 44 weeks. The goal is to collect real-world information about how ch…

This study is testing whether a new drug, PF-08634404, works better than the current standard treatment for people whose colorectal cancer has spread. About 800 adults who haven't yet received treatment for their advanced cancer will be randomly assigned to get either the new dru…

This study is monitoring the safety and real-world effectiveness of the antibiotic Zavicefta after its approval in Korea. It involves about 600 patients aged 3 months and older who are prescribed Zavicefta for serious infections like complicated abdominal infections, urinary trac…

This study is testing a new medicine called PF-08634404 for adults with advanced kidney cancer that has spread. Researchers want to see if the medicine is safe and effective when given alone or with other cancer drugs. The study is recruiting 224 adults who haven't received any t…

This program provides special early access to the drug etrasimod for patients with severe ulcerative colitis who have no other treatment options. It is for individuals who have tried and failed at least three other available therapies or cannot tolerate them. The program allows d…

This early-stage study aims to understand how the body absorbs a new weight management medicine when it's injected into different areas, like the thigh, arm, or abdomen. It will involve 54 adults who are overweight or have obesity, who will receive a single dose. Researchers will…

This study is testing a new weekly injection called MET097 to help adults with type 2 diabetes and overweight or obesity lose weight and better control their blood sugar. About 1,000 participants will receive either the real injection or a placebo (a shot with no medicine) for ab…

This early-stage study is testing whether two drugs—elranatamab (given as an injection) and iberdomide (taken as a pill)—can be safely combined to treat multiple myeloma that has returned or stopped responding to previous treatments. The trial will enroll 87 adults who have alrea…

This study is monitoring the safety and effectiveness of the approved eczema medication Cibinqo (abrocitinib) in real-world medical practice in Korea. It will follow about 1,100 patients, aged 12 and older with moderate to severe atopic dermatitis, for approximately one year afte…

This early-stage study is testing the safety and effects of an experimental cancer drug called PF-08046876 in adults with advanced solid tumors. The drug is an antibody drug conjugate designed to target and kill cancer cells. Researchers will give the drug through an IV to about …

This early-stage study is testing a new oral medication called PF-08032562, both alone and in combination with other cancer drugs, for people with advanced or metastatic breast or colorectal cancer. The main goals are to find a safe dose and see how the body processes the drug. R…

This study aims to see if a medicine called rimegepant can help prevent migraines in teenagers aged 12-17 who have chronic migraines (15 or more headache days a month). For the first 3 months, half the participants will take rimegepant every other day and half will take a placebo…

This study is monitoring the safety of Somatrogon, a growth hormone injection treatment for children with growth hormone deficiency in India. Researchers will follow 50 children aged 3 and older for up to 3 years to track any side effects they experience while receiving this trea…

This study is testing a new antibiotic combination (Aztreonam-Avibactam) for children hospitalized with serious bacterial infections. It aims to see how the drug works in the body, if it's safe, and if it helps clear infections compared to current standard treatments. The study w…

This study aims to see how well the medication etrasimod works for adults with moderate-to-severe ulcerative colitis in everyday, real-world settings. It will follow 300 patients for one year as they take the drug as part of their standard care. The main goal is to measure how ma…

This study is testing the safety and how the body processes a new combination of two antibiotics (aztreonam and avibactam) in babies under 9 months old who have serious bacterial infections. The goal is to find the right dose and see if it's safe for this vulnerable age group. Th…

This study is testing whether adding an experimental drug called mevrometostat to a standard prostate cancer medicine (enzalutamide) works better than current standard treatments for men with advanced prostate cancer that has spread and is no longer responding to prior therapy. I…

This early-stage study is testing a new drug called PF-08052667 for adults with a type of bladder cancer that hasn't spread into the muscle but is likely to return. The drug is given directly into the bladder, either by itself or combined with other standard treatments. The main …

This study is testing a new oral medication called osivelotor for people with sickle cell disease. The main goals are to see if the pill can safely increase hemoglobin levels and reduce the number of painful crises (VOCs) that require medical care. The trial involves nearly 400 p…

This study is testing whether a new injection medicine called PF-07275315 can help adults with moderate-to-severe asthma that isn't well controlled by their current treatments. Over 12 weeks, 252 participants will receive either the actual medicine or placebo shots to compare saf…

This study continues testing an experimental medicine for pulmonary arterial hypertension (PAH), a serious condition where high blood pressure damages the heart and lungs. It follows 36 adults who already took the medicine in an earlier trial to check long-term safety and effects…

This study is testing a new medicine called elranatamab, given as a weekly injection, against several standard combination therapies for multiple myeloma that has come back or stopped responding to previous treatments. It will involve about 492 adults whose cancer has progressed …

This program provides early access to the investigational drug ritlecitinib for patients with severe alopecia areata who have lost at least 50% of their scalp hair. It's designed for people who haven't responded well to or can't tolerate other standard treatments available in the…

This study is testing whether a medicine called abrocitinib can safely and effectively control moderate-to-severe eczema in children aged 6 to under 12. About 150 children will be randomly assigned to receive either the real medicine or a placebo (a look-alike pill with no medici…

This study aims to evaluate the long-term safety and effectiveness of marstacimab, a preventive injection treatment, for people with severe hemophilia A or B. It includes about 245 participants, both children and adults, who have already been in previous marstacimab studies. The …

This study is testing whether a 5-day course of an oral medication called ibuzatrelvir can prevent people with mild-to-moderate COVID-19 from getting severely sick and needing hospital care. It is for adults and adolescents (12+) who have COVID-19 symptoms and are at high risk fo…

This is the first time a new drug called PF-07832837 is being tested in people. The main goal is to see if it is safe and how the body handles it. The study will involve both healthy volunteers and people with moderate to severe atopic dermatitis (eczema) to check for side effect…

This is a first-in-human study to test the safety and find the right dose of a new oral medicine, PF-07934040. It is being tested alone and in combination with other cancer drugs in people with advanced lung, colorectal, or pancreatic cancer that has a specific genetic change cal…

This study aims to learn about the long-term safety and effectiveness of the medicine ritlecitinib for treating severe alopecia areata, a condition that causes significant hair loss. It is for children and teenagers who have already finished one of two previous Pfizer studies for…

This study is testing whether new drug combinations can better control multiple myeloma that has returned or stopped responding to previous treatments. It will compare two experimental approaches using the drugs elranatamab and daratumumab against a current standard therapy. The …

This study is observing how well the drug tofacitinib works for people with ulcerative colitis in everyday Swedish healthcare. It will track about 120 adult patients who are already prescribed this medication by their doctor to see if it reduces their gut inflammation and symptom…

This two-year study aims to understand the long-term safety and effectiveness of an oral liquid medication called abrocitinib for children aged 2 and older with moderate-to-severe eczema (atopic dermatitis). It will enroll about 500 children globally, including some who have take…

This study aims to find out if a drug called Inotuzumab Ozogamicin works better than standard therapy for children with high-risk relapsed B-cell ALL. About 100 children aged 1 to 18 will receive one cycle of either treatment, then be followed for up to 5 years. The main goal is …

This study is testing whether a new drug (PF-07220060) combined with letrozole works better than current standard treatments for advanced breast cancer. It's for adults with a specific type of breast cancer that has spread and who haven't had any prior treatment for their advance…

This study is testing an experimental drug called disitamab vedotin for people with advanced breast cancer that has spread and has a protein called HER2 on the tumor cells. It is for patients whose cancer has continued to grow despite receiving standard treatments, including othe…

This study provides continued access to the cancer drugs encorafenib and/or binimetinib for patients who were already taking them in earlier clinical trials and are still benefiting. It allows these patients to keep receiving the same treatment for up to about 5 years while docto…

This study is testing two new injectable medicines (PF-07275315 and PF-07264660) for adults with moderate-to-severe atopic dermatitis (eczema) who haven't gotten enough relief from skin creams. Participants will receive either one of the study medicines or a placebo (inactive sho…

This study is testing whether a medication called rimegepant can safely prevent migraines in children and adolescents aged 6 to 18. Researchers will compare the drug to a placebo (a pill with no medicine) to see if it reduces the number of migraine days each month over 12 weeks. …

This study is observing how well the oral medication abrocitinib works for people with moderate-to-severe eczema (atopic dermatitis) in real-world clinics. It focuses on about 150 patients aged 12 and older who did not get enough relief or could not tolerate up to two previous bi…

This study is testing a daily pill called etrasimod to see if it can help control the symptoms of moderate to severe ulcerative colitis in teenagers. It will involve about 36 participants aged 12 to 18 and will last for one year, with an option to continue for up to five years. T…

This study is testing whether a new daily pill (PF-07248144) combined with a standard hormone injection (fulvestrant) works better than current standard treatments for advanced breast cancer. It is for people whose cancer has continued to grow despite prior hormone-based therapy.…

This study is testing whether a new oral medicine, PF-07328948, is safe and can help control heart failure in adults who are already on standard treatments. About 620 participants will take either the study medicine or a placebo pill daily for 36 weeks. Researchers will measure i…

This study provides continued access to the drug elranatamab for people with multiple myeloma who benefited from it in earlier Pfizer-sponsored trials. It allows up to 80 participants to keep receiving the treatment while researchers monitor its long-term safety. The goal is to c…

This study is testing a new drug, PF-08634404, when used alongside other cancer medicines in adults with advanced non-small cell lung cancer that has spread. The main goals are to see if the drug combinations are safe and if they can help control the cancer. The study is in early…

This study aims to understand the long-term safety and effectiveness of the drug dazukibart for adults with dermatomyositis or polymyositis, two rare diseases that cause painful muscle weakness and inflammation. The trial is open to people who previously completed a related 52-we…

This study is monitoring the safety and effectiveness of the arthritis medication Xeljanz XR in routine medical practice in Korea. It will follow at least 200 adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who are already prescribed this medicati…

This study is testing a new drug called PF-08634404 to see if it is safe and effective for treating advanced liver cancer that cannot be removed by surgery. It will be given alone or combined with another drug (ipilimumab) to 138 adults who have not had other whole-body treatment…

This study is testing whether a daily oral pill called ritlecitinib can safely reduce painful skin lumps in adults with moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease. The 240 participants, whose HS did not improve with prior antibiotic trea…

This study is testing whether a higher dose (100 mg) of the medication ritlecitinib is safe and works better than the standard 50 mg dose for treating severe alopecia areata, a condition that causes significant hair loss. It will involve about 550 participants aged 12 and older w…

This Phase 3 study is testing whether the investigational drug dazukibart can help control symptoms of dermatomyositis and polymyositis—rare autoimmune diseases that cause painful muscle inflammation and weakness. The trial will enroll 318 adults who are already taking standard m…

This early-stage study is testing a new oral medicine called PF-07799933, both alone and combined with other drugs, for people with advanced solid tumors that have a specific BRAF gene change and have stopped responding to standard treatments. The main goals are to find a safe do…

This study aims to monitor the safety and effectiveness of the drug Mylotarg in adults newly diagnosed with a type of blood cancer called acute myeloid leukemia (AML). It will observe 165 patients in Korea who are already receiving Mylotarg as part of their standard hospital care…

This study is testing whether a new injectable medication called PF-06835375 can safely increase platelet counts in adults with moderate to severe immune thrombocytopenia (ITP). Participants will receive monthly injections for 3-4 months while researchers monitor their platelet l…

This early-stage study is testing the safety of two new drug combinations for people with multiple myeloma that has returned or stopped responding to standard treatments. About 90 participants will receive either a three-drug combination or a two-drug combination to see how well …

This study is testing a new oral medicine called mevrometostat, alone and combined with an existing drug (enzalutamide), for men with advanced prostate cancer that has worsened despite prior treatment. The main goals are to find a safe dose and see if the treatment can help contr…

This large, late-stage study is testing whether adding a new drug called mevrometostat to a standard prostate cancer drug (enzalutamide) works better than the standard drug alone. It will involve 900 men with advanced prostate cancer that has spread and stopped responding to horm…

This early-stage study is testing the safety and initial effects of a new oral medicine, PF-07799544, when taken with another drug, PF-07799933. It is for adults with advanced solid tumors, like melanoma or lung cancer, that have a specific genetic change called a BRAF V600 mutat…

This study is testing whether a daily pill called ritlecitinib can help regrow scalp hair in children aged 6 to 12 who have lost at least half their hair due to severe alopecia areata. About 225 children will be randomly assigned to receive either one of two doses of the study me…

This early-stage study is testing the safety and how children's bodies process a migraine medicine called Zavegepant, given as a single nasal spray dose. It involves 16 children aged 6 to 12 who have a history of migraines. The main goal is to understand how the medicine behaves …

This study is testing whether adding a new drug called ponsegromab to standard chemotherapy can help adults with advanced pancreatic cancer who are experiencing severe weight and muscle loss (cachexia). The main goal is to see if ponsegromab helps patients gain or maintain body w…

This study is testing whether a medication called rimegepant can safely and effectively stop migraine attacks in children and teenagers. It will involve about 2,100 participants aged 6 to 17 who experience moderate to severe migraines. The trial compares rimegepant against a plac…

This study aims to check the long-term safety of a migraine medicine called rimegepant in children and teenagers aged 6 to 18. Researchers will enroll 600 participants who experience migraines to monitor for side effects over time. The focus is on understanding how well young peo…

This study aims to see if two different versions of a migraine medication work the same way in the body. Pfizer is recruiting 64 healthy adults to take both versions and compare how they're absorbed. The goal is to understand if a new formulation could be just as effective as the…

This study aims to understand the long-term heart health of young people under 21 who developed heart inflammation (myocarditis/pericarditis) shortly after receiving the Pfizer COVID-19 vaccine. Researchers will follow about 400 participants for up to 5 years, performing heart im…

This early-stage study aims to understand how eating a meal affects how the body absorbs and processes an experimental drug called atirmociclib. It will involve 72 healthy adult volunteers who will take different doses of the drug after eating. The main goal is to measure drug le…

This is an early safety study testing a new medicine called PF-07985631, which is being developed to treat a kidney disease called IgA nephropathy. The study involves 92 healthy adult volunteers who will receive either the study medicine or a placebo (inactive substance) via inje…

This study aims to prove that prazosin capsules, a blood pressure medication, work exactly the same whether they are made at a factory in Puerto Rico or one in Italy. Healthy adult volunteers will take capsules from each location so researchers can compare how the medicine is abs…

This study aims to understand how a common drug, carbamazepine, changes how the body processes an experimental Pfizer drug called PF-07248144. It involves 12 healthy adults who will take PF-07248144 alone and then with carbamazepine. Researchers will take blood samples to measure…

This early-stage study aims to understand how a new oral medicine called PF-07328948 is processed by the body in people with different levels of kidney function. It will enroll 28 adults, including both healthy participants and those with moderate to severe long-term kidney impai…

This early-stage study aims to understand how a new medicine, PF-07328948, is processed in the bodies of people with different levels of liver impairment compared to healthy people. It will enroll 26 adults, some with stable liver disease and some without, who will take a single …

This study aims to observe how patients with moderate-to-severe atopic dermatitis (eczema) respond to the medication abrocitinib in real-world, everyday clinical practice. It will follow 200 patients aged 12 and older who are newly prescribed this medication by their doctor. Rese…

This study aims to monitor the safety of the Prevenar 20 pneumococcal vaccine in routine medical practice in Korea. It will enroll 660 participants aged 6 weeks and older who receive the vaccine as part of their normal healthcare. Researchers will track any side effects or reacti…

This is an early safety study for a potential new medicine called PF-07985631, which is being developed to treat a serious kidney disease called IgA nephropathy. The study will give single injections of the drug to healthy adult volunteers to check for side effects and see how th…

This study aims to understand if the migraine medication rimegepant is safe during pregnancy. It will follow pregnant women with migraines, some who take the drug and some who do not, to track the health of both mother and baby for up to a year after birth. The goal is to collect…

This study aims to understand if the eczema medication abrocitinib (CIBINQO) is safe for use during pregnancy. Researchers will follow 400 pregnant women with moderate-to-severe eczema—some taking the drug and some not—and track their babies' health through the first year of life…

This study aims to understand how two existing medications (itraconazole and probenecid) affect how the body processes a single dose of a new, experimental drug called PF-07220060. It involves 28 healthy adult volunteers who will take the new drug alone and then again while takin…

This study aims to understand how much of the medication etrasimod passes into breast milk when taken by breastfeeding women. Eight healthy women who are breastfeeding will take the drug daily for one week while staying at a research facility. Researchers will measure drug levels…

A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data colle…